Aug 2026· IEEE transactions on computational biology and bioinformatics· Vol PP· 0 citations
Medicine
TL;DR
The key innovation of LOGIC lies in constructing a dictionary of functional groups and symptoms, and performing a simple and intuitive multi-hot encoding of drugs and diseases at the micro-scale, and in employing large language models (LLMs) to derive the meso-scale features of diseases without requiring additional domain knowledge.
Abstract
Predicting drug-disease interactions (DSI) is a pivotal task in computational drug discovery, aiming to identify potential therapeutic or adverse effects between drugs and diseases. Current methodologies primarily model on two levels of features: the macroscopic level, utilizing network topology, and the mesoscopic level, leveraging molecular-level features. While valuable, these approaches share a common shortcoming: they frequently fail to capture fine-grained, mechanistic interactions. This refers to the specific interplay between drug functional groups and disease symptoms that underpins pharmacological effects. To address this limitation, we propose LOGIC, a novel model for LLM-driven cross-scale feature coupling for DSI prediction. LOGIC comprehensively models drug and disease representations across micro-, meso-, and macro-scales. The key innovation of LOGIC lies in constructing a dictionary of functional groups and symptoms, and performing a simple and intuitive multi-hot encoding of drugs and diseases at the micro-scale, and in employing large language models (LLMs) to derive the meso-scale features of diseases without requiring additional domain knowledge. LOGIC mainly consists of four modules: (1) Drug-disease micro-scale feature learning; (2) Drug-disease meso-scale feature learning; (3) Drug-disease macro-scale feature learning; and (4) cross-scale feature coupling prediction, which integrates micro-, meso- and macro-scale features for both drugs and diseases, and employs the matrix multiplication operation to model fine-grained feature interactions in the dimension level for DSI prediction. Extensive experiments conducted on multiple datasets validate the effectiveness and scalability of LOGIC.
Current computational approaches for drug design typically focus on generating molecules conditioned on specific targets or general molecular properties, often neglecting the influence of disease context on target behavior and therapeutic outcomes. To address this gap, we introduce DrugGen-2, a novel generative model that designs small molecules conditioned on both disease ontology and target protein sequences. DrugGen-2 was developed by fine-tuning a pre-trained GPT-2 model on a curated dataset of approved drugs linked to their diseases and targets, using a two-step strategy of supervised fine-tuning followed by reinforcement learning via group relative policy optimization (GRPO). This process was guided by reward functions optimizing for chemical validity, novelty, diversity, and high predicted binding affinity. When evaluated on five protein targets relevant to diabetic nephropathy, DrugGen-2 significantly outperformed baseline models (DrugGPT and DrugGen). It demonstrated a superior capacity to generate unique molecules, exhibited greater structural similarity to approved drugs, and achieved improved predicted binding affinities across all targets. Molecular docking analyses further supported these findings, identifying candidate ligands with strong binding potential, including compounds with predicted affinities (-9.917, -9.485, and -9.367) exceeding those of reference drugs such as enalapril for angiotensin-converting enzyme (-8.283). By integrating disease-specific context into molecular generation, DrugGen-2 advances AI-assisted drug discovery, offering a powerful tool for de novo design and drug repurposing that accounts for the complex interplay between diseases and molecular targets.
Ali Motahharynia, Mohammadreza Ghaffarzadeh-Esfahani, Mahsa Sheikholeslami et al.· 0 citations
MKASynergy, an adaptive drug synergy prediction method based on a mixture-of-experts kernel mechanism, achieves competitive predictive performance and visualization analysis confirms the model’s effectiveness in feature decoupling and helps interpret latent drug synergistic mechanisms.
Cundong Lin, Jiancheng Ni, Ying Yang et al.· Network Modeling Analysis in...· 0 citations
DC-MetaMG, a deep learning framework based on a causal disentanglement strategy that models association responses as the synergistic interplay between two complementary mechanisms: static binding and dynamic regulation, is proposed, demonstrating its suitability for training scenarios involving complex biological information.
Runzhou Tang, Xi Zhou, Yujie Qi et al.· IEEE journal of biomedical a...· 0 citations
SGTL-DDA is proposed, a novel graph transformer framework designed to incorporate structural information and domain-specific knowledge from heterogeneous biological information networks (HBINs) that successfully identifies both known therapeutics and novel repositioning candidates, supported by molecular docking results and literature evidence.
Bowei Zhao, Hui Zhao, Yu-an Huang et al.· IEEE transactions on computa...· 0 citations
Empirical evaluation and robustness experiments show that M2DDI maintains high predictive accuracy even when modality-specific information is partially missing, outperforming existing methods under similar conditions and establish M2DDI as an effective and mechanism-aware solution for comprehensive DDI prediction.
Runqing Xu, Siyi Liu, Haoyang Li et al.· Proceedings of the 32nd ACM...· 0 citations
IHLO-DTI, a novel prediction model based on an improved hypergraph neural network and Laplacian matrix optimization, can effectively capture high-order many-to-many interactions between drugs and targets, improving prediction accuracy and robustness.
Guolongwei Dai, Tao Luo, Dandan Li et al.· ACS Synthetic Biology· 0 citations